SCHEMBL5942150

SCHEMBL5942150

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 2/20 0.50
HPGD P15428 2/20 0.50
HSD17B10 Q99714 2/20 0.50
USP2 O75604 1/20 0.50
CYP2C19 P33261 1/20 0.50
FAAH O00519 3/20 0.49
CNR1 P21554 4/20 0.41
ALOX12 P18054 1/20 0.41
EPHX2 P34913 6/20 0.40
MAPT P10636 2/20 0.40
CNR2 P34972 2/20 0.40
FFAR1 O14842 1/20 0.36
CYP19A1 P11511 1/20 0.36
RXRA P19793 1/20 0.36
PPARG P37231 1/20 0.36
OXER1 Q8TDS5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16626063 0.91 ALDH1A1 (0.47) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5941832 0.90 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5942132 0.89 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5942124 0.88 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5941812 0.85 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5941930 0.84 CNR1 (0.45) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5942129 0.83 ALDH1A1 (0.45) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5941847 0.81 CNR1 (0.41) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5940761 0.81 KDM4E (0.61) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL5941932 0.80 ALDH1A1 (0.48) ALDH1A1KDM4EHPGDHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210169905-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2021-06-10 US disclosed
US-20200046738-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2020-02-13 US disclosed
US-20170246193-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2017-08-31 US disclosed
US-20170246193-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2017-08-31 US disclosed
US-9708245-B2 Fatty acid acylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2017-07-18 US disclosed
US-9708245-B2 Fatty acid acylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2017-07-18 US disclosed
US-9458094-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2016-10-04 US disclosed
US-9458094-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2016-10-04 US disclosed
US-20160083336-A1 FATTY ACID ACYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2016-03-24 US disclosed
US-20160083336-A1 FATTY ACID ACYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2016-03-24 US disclosed
US-20120238530-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-09-20 US disclosed
US-20120238585-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-09-20 US disclosed
US-20120238586-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2012-09-20 US disclosed
US-8173831-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2012-05-08 US disclosed
US-8173831-B2 Fatty acid acetylated salicylates and their uses CATABASIS PHARMACEUTICALS, INC. (US) 2012-05-08 US disclosed
US-20100184730-A1 Fatty Acid Acylated Salicylates and Their Uses CATABASIS PHARMACEUTICALS, INC. 2010-07-22 US disclosed
US-20100184730-A1 Fatty Acid Acylated Salicylates and Their Uses CATABASIS PHARMACEUTICALS, INC. 2010-07-22 US disclosed
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2010-02-18 US disclosed
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010006085-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES CATABASIS PHARMACEUTICALS, INC. (US) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200046738-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 ALDH1A1 285/4885KDM4E 2493/4885HPGD 510/4885
US-20120238585-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 ALDH1A1 285/4885KDM4E 2493/4885HPGD 510/4885
US-20120238586-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 ALDH1A1 285/4885KDM4E 2493/4885HPGD 510/4885
US-20170246193-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 ALDH1A1 285/4885KDM4E 2493/4885HPGD 510/4885
US-20100041748-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 ALDH1A1 285/4885KDM4E 2493/4885HPGD 510/4885
US-20210169905-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 ALDH1A1 285/4885KDM4E 2493/4885HPGD 510/4885
US-20160083336-A1 FATTY ACID ACYLATED SALICYLATES AND THEIR USES FADS1, FASN, ALOX5 ALDH1A1 230/4885KDM4E 3068/4885HPGD 338/4885
US-20120238530-A1 FATTY ACID ACETYLATED SALICYLATES AND THEIR USES FASN, ACACA, FABP4 ALDH1A1 285/4885KDM4E 2493/4885HPGD 510/4885
US-20100184730-A1 Fatty Acid Acylated Salicylates and Their Uses FADS1, FASN, ALOX5 ALDH1A1 230/4885KDM4E 3068/4885HPGD 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.